IP Library Granted Patent US 8,551,739
Granted Patent B2
US 8,551,739 · App. 11/894,817 · Granted Oct 8, 2013

Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase

Inventor: Stewart Shuman (New York, NY)
Assignee: Memorial Sloan-Kettering Cancer Center
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,551,739
App. No.
11/894,817
Granted
Oct 8, 2013
Kind
B2
Abstract

This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme. This invention provides a method of ligating duplex DNAs, a method of molecular cloning of DNA, a method of synthesizing polynucleotides, and a method of gene targeting. Lastly, this invention provides a recombinant DNA molecule composed of segments of DNA which have been joined ex vivo by the use of a sequence specific topoisomerase and which has the capacity to transform a suitable host cell comprising a DNA sequence encoding polypeptide activity.

Claims (12)

1. A method of producing a ligated DNA molecule comprising:

contacting an acceptor duplex DNA molecule with a donor duplex DNA molecule that comprises:

a sequence specific type I topoisomerase bound on at least one end of the molecule and at least one of an origin of replication and a selection marker,

under conditions in which the sequence-specific type I topoisomerase ligates the donor duplex DNA molecule to the acceptor duplex DNA molecule, to produce a ligated DNA molecule.

2. The method of claim 1 , wherein the type I topoisomerase is a vaccinia type I topoisomerase.

3. The method of claim 1 , wherein the acceptor duplex DNA molecule has a 5′ terminal hydroxyl on each end.

4. The method of claim 1 , further comprising introducing the ligated DNA molecule into a cell.

5. The method of claim 4 , wherein the cell is an Escherichia coli cell.

6. The method of claim 1 , wherein the donor duplex DNA molecule comprises an origin of replication.

7. The method of claim 1 , wherein the donor duplex DNA molecule comprises a selection marker.

8. The method of claim 1 , wherein the acceptor duplex DNA molecule is generated by a polymerase chain reaction (PCR).

9. The method of claim 1 , wherein the donor duplex DNA molecule is linear.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 27, 2012
From: SLOAN-KETTERING INSTITUTE FOR CANCER RES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027933/0088 →
Continuity (5)
Continuation 11368299 · Mar 3, 2006
Continuation 10360478 · Feb 7, 2003
Continuation 08898517 · Jul 22, 1997
Division 08358344 · Dec 19, 1994
Related Publication 20090068708A1 · Mar 12, 2009